As part of Imcheck Therapeutics' Series B €48 million fundraising, Dechert advised a group of new investors (including InnoBio, Bpifrance Participations, Capital Agent, Wellington Partners Venture Capital and Alexandria Venture Investments).
This fundraising event will enable ImCheck Therapeutics to advance its clinical pipeline of antibodies targeting gamma delta T cells against cancer and autoimmune diseases.
Imcheck Therapeutics previously raised €20 million in 2017.
The Dechert team advising the group of new investors included:
- in corporate: Anne-Charlotte Rivière, Claire Tanguy and Johann Gandilhon
- in labor: Philippe Thomas, Thibault Meiers, Viviane Valilou
- in intellectual property: Marie Fillon, Louis de Chezelles
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
Subscribe to Dechert Updates